Interestingly, clinically approved drugs for human pancreatic cancer such as paclitaxel, irinotecan, and erlotinib27 all showed negative correlations with ITGα3 expression, indicating that ITGα3 might be potentially involved in chemo-resistance of pancreatic cancer. This evidence concerns the gene ITGA3 and familial pancreatic carcinoma.